• Pharmacists Center

    The Pharmacists Center features helpful resources, links, and tools supporting healthcare provider and patient education as well as useful information for practicing oncology pharmacists. Pharmacists Center

  • Nurses Center

    The Nurses Center features helpful resources, links, and tools supporting nurse and patient education as well as the practice of oncology nursing. Nurses Center

  • Fellows Center

    The Fellows Center features helpful resources, links, and tools supporting oncology fellows' education and current clinical practice. Fellows Center

References

  1. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation, and drug resistance. Biochim Biophys Acta. 2007;1773:1263-1284.

  2. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004;4:937-947.

  3. McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and I3K/PTEN/AKT pathways in malignant transformation and drug resistance. Advan Enzyme Regul. 2006;46:249-279.

  4. Claperón A, Therrien M. KSR and CNK: two scaffolds regulating RAS-mediated RAF activation. Oncogene. 2007;26:3143-3158.

  5. Ussar S, Voss T. MEK1 and MEK2, different regulators of the G1/S transition. J Biol Chem. 2004;279:43861-43869.

  6. Wong K-K. Recent developments in anti-cancer agents targeting the Ras/Raf/MEK/ERK pathway. Recent Pat Anticancer Drug Discov. 2009;4:28-35.

  7. Johnston S. XL518, a potent, selective, orally bioavailable MEK1 inhibitor, downregulates the Ras/Raf/MEK/ERK pathway in vivo, resulting in tumor growth inhibition and regression in preclinical models. Presented at: AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics; October 22, 2007; San Francisco, CA. Abstract C209.